Kyung Nam Pharm Co Ltd
KOSDAQ:053950
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (16.8), the stock would be worth ₩-85.85 (113% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -125.9 | ₩642 |
0%
|
| Industry Average | 16.8 | ₩-85.85 |
-113%
|
| Country Average | 8.5 | ₩-43.55 |
-107%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
K
|
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
|
50.2B KRW | -125.9 | -5.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28 | 41.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.5 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 7.2 | 17 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Kyung Nam Pharm Co Ltd
Glance View
Kyungnam Pharm Co., Ltd. manufactures pharmaceutical products. The company is headquartered in Uiryeong-Gun, Gyeongsangnam-Do. The company went IPO on 2001-11-06. The firm's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The firm provides vitamin products under the brand name LEMONA. The company supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.
